Defence Research

Defence Therapeutics is a clinical-stage biotechnology company focused on developing the next generation of vaccines and antibody-drug conjugates (ADCs) using its proprietary Accum platform. The Accum technology is designed to enhance the intracellular delivery of biological molecules by facilitating their escape from endosomes, thereby increasing the efficacy of therapeutic payloads. The company's pipeline includes programs for cancer immunotherapy, infectious disease vaccines, and enhanced ADC delivery systems. By improving the precision and potency of drug delivery, Defence Therapeutics aims to address significant unmet needs in oncology and infectious disease management.